CORD-19:0376103fd7863b10e41a0f59fe226be9765f34c7 / 23396-23747 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T112","span":{"begin":0,"end":351},"obj":"Sentence"},{"id":"TextSentencer_T112","span":{"begin":0,"end":351},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Administration of bone marrow-derived MSCs, either intratracheally, intravenously, or intraperitoneally, have ameliorated numerous aspects of neonatal lung injury, as evident by mitigation of lung inflammation, prevention of lung vascular damage and alveolar growth arrest, inhibition of lung fibrosis, and improvement in exercise tolerance (Fig. 3) ."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T112","span":{"begin":0,"end":351},"obj":"Sentence"}],"text":"Administration of bone marrow-derived MSCs, either intratracheally, intravenously, or intraperitoneally, have ameliorated numerous aspects of neonatal lung injury, as evident by mitigation of lung inflammation, prevention of lung vascular damage and alveolar growth arrest, inhibition of lung fibrosis, and improvement in exercise tolerance (Fig. 3) ."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T105","span":{"begin":156,"end":162},"obj":"Disease"},{"id":"T106","span":{"begin":197,"end":209},"obj":"Disease"}],"attributes":[{"id":"A105","pred":"mondo_id","subj":"T105","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A106","pred":"mondo_id","subj":"T106","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"}],"text":"Administration of bone marrow-derived MSCs, either intratracheally, intravenously, or intraperitoneally, have ameliorated numerous aspects of neonatal lung injury, as evident by mitigation of lung inflammation, prevention of lung vascular damage and alveolar growth arrest, inhibition of lung fibrosis, and improvement in exercise tolerance (Fig. 3) ."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T149","span":{"begin":18,"end":29},"obj":"Body_part"},{"id":"T150","span":{"begin":151,"end":155},"obj":"Body_part"},{"id":"T151","span":{"begin":192,"end":196},"obj":"Body_part"},{"id":"T152","span":{"begin":225,"end":229},"obj":"Body_part"},{"id":"T153","span":{"begin":288,"end":292},"obj":"Body_part"}],"attributes":[{"id":"A149","pred":"uberon_id","subj":"T149","obj":"http://purl.obolibrary.org/obo/UBERON_0002371"},{"id":"A150","pred":"uberon_id","subj":"T150","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A151","pred":"uberon_id","subj":"T151","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A152","pred":"uberon_id","subj":"T152","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A153","pred":"uberon_id","subj":"T153","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Administration of bone marrow-derived MSCs, either intratracheally, intravenously, or intraperitoneally, have ameliorated numerous aspects of neonatal lung injury, as evident by mitigation of lung inflammation, prevention of lung vascular damage and alveolar growth arrest, inhibition of lung fibrosis, and improvement in exercise tolerance (Fig. 3) ."}